Get the Stockscreener App
1.53
10.00%
-0.17
Pre-market:
1.49
-0.04
-2.61%
Renovaro Biosciences Inc stock is currently priced at $1.53, with a 24-hour trading volume of 1.04M.
It has seen a -10.00% decreased in the last 24 hours and a -47.60% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $1.75 pivot point. If it approaches the $1.51 support level, significant changes may occur.
Previous Close:
$1.70
Open:
$1.79
24h Volume:
1.04M
Market Cap:
$219.81M
Revenue:
-
Net Income/Loss:
$-41.23M
P/E Ratio:
-2.1549
EPS:
-0.71
Net Cash Flow:
$-11.54M
1W Performance:
-29.49%
1M Performance:
-47.60%
6M Performance:
-45.36%
1Y Performance:
+0.00%
1D Range:
$1.50
$2.10
52W Range:
$1.50
$5.25
Renovaro Biosciences Inc Stock (RENB) Company Profile
Name
Renovaro Biosciences Inc
Sector
Industry
Phone
305 918 1980
Address
Century City Medical Plaza, Suite 906 2080 Century Park East, Los Angeles
Renovaro Biosciences Inc Stock (RENB) Latest News
Renovaro Inc. Proudly Announces the Appointment Of Professor Dr. Geert Kazemier as the Chairman of its Scientific Advisory Board, A Move That Heralds a New Era of Innovation and Progress in its Mission to Reshape Cancer Screening, Diagnosis, and Patient Care
GlobeNewswire Inc.
Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga
Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace
GlobeNewswire Inc.
Statement of Renovaro Inc
GlobeNewswire Inc.
Why IPG Photonics Shares Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga
Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace
GlobeNewswire Inc.
Renovaro Biosciences Inc Stock (RENB) Financials Data
Renovaro Biosciences Inc (RENB) Net Income 2024
RENB net income (TTM) was -$41.23 million for the quarter ending December 31, 2023, a +62.03% increase year-over-year.
Renovaro Biosciences Inc (RENB) Cash Flow 2024
RENB recorded a free cash flow (TTM) of -$11.54 million for the quarter ending December 31, 2023, a +4.34% increase year-over-year.
Renovaro Biosciences Inc (RENB) Earnings per Share 2024
RENB earnings per share (TTM) was -$0.70 for the quarter ending December 31, 2023, a +66.02% growth year-over-year.
About Renovaro Biosciences Inc
Renovaro Biosciences Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer. The company's product pipeline includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a gene therapy curative treatment for HBV. It develops ENOB-DC-11, an allogeneic dendritic cell therapeutic vaccine for solid tumors; ENOB-DC-12-XX, allogeneic dendritic cell therapeutic vaccine for other solid tumors; and ENOB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. Enochian Biosciences, Inc. has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Enochian Biosciences, Inc. and changed its name to Renovaro Biosciences Inc. in August 2023. The company was incorporated in 2017 and is headquartered in Los Angeles, California.
1.53%
3.38%
Cap:
|
Volume (24h):